Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01337
|
|||||
| Drug Name |
Tenofovir alafenamide
|
|||||
| Synonyms |
(S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate; AK109983; EL9943AG5J; GS 7340; GS-7339; GS-7340; GS7340; J4414G3BUK; L-Alanine, N-((S)-(((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester; TENOFOVIR ALAFENAMIDE; Tenofovir Alafenamide (GS-7340); Tenofovir Alafenamide [USAN:INN]; UNII-EL9943AG5J; UNII-J4414G3BUK; Vemlidy
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Chronic hepatitis B infection [ICD11: 1E51.0] | Phase 3 | [1] | |||
| Human immunodeficiency virus infection [ICD11: 1C62.Z] | Phase 3 | [1] | ||||
| Therapeutic Class |
Antiviral Agent
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C21H29N6O5P
|
|||||
| Canonical SMILES |
CC(C)OC(=O)C(C)NP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OC3=CC=CC=C3
|
|||||
| InChI |
InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1
|
|||||
| InChIKey |
LDEKQSIMHVQZJK-CAQYMETFSA-N
|
|||||
| CAS Number |
CAS 379270-37-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 476.5 | Topological Polar Surface Area | 144 | ||
| Heavy Atom Count | 33 | Rotatable Bond Count | 12 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 10 | |||
| XLogP |
1.9
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:90926
|
|||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | ||
| References | ||||||
| 1 | ClinicalTrials.gov (NCT03122262) ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy | |||||
| 2 | Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):465-472. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.